

10/791578

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.88

1.09

FILE 'CAPLUS' ENTERED AT 19:40:57 ON 19 FEB 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Feb 2006 VOL 144 ISS 9

FILE LAST UPDATED: 17 Feb 2006 (20060217/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 12

L3 7 L2

=> d 13 5-7 bib abs hitstr

L3 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:575065 CAPLUS

DN 137:140776

TI Preparation of piperidiny1 and piperaziny1 amino acid derivatives as melanocortin receptor agonists

IN Backer, Ryan Thomas; Briner, Karin; Doecke, Christopher William; Fisher, Matthew Joseph; Kuklish, Steven Lee; Mancuso, Vincent; Martinelli, Michael John; Mullaney, Jeffrey Thomas; Xie, Chaoyu

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 263 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2002059107	A1	20020801	WO 2002-US516	20020123
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,			

KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
 GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
 GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2433025 AA 20020801 CA 2002-2433025 20020123
 EP 1368339 A1 20031210 EP 2002-701923 20020123
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2004521117 T2 20040715 JP 2002-559409 20020123
 US 2004058936 A1 20040325 US 2003-466249 20030711
 PRAI US 2001-263595P P 20010123
 WO 2002-US516 W 20020123
 OS CASREACT 137:140776; MARPAT 137:140776
 GI



AB The invention relates to melanocortin receptor (MC-R) agonists I [G = CR1 or N; LL1 = H2 or oxo; T = isoquinolinyl or tetrahydro deriv., isoindolinyl, or piperazinyl; n = 0-8; R = H, OH, CN, NO2, halo, alkyl, acyl, etc.; R1 = H, alkyl, alkylcarbonyl, (D)phenyl, (D)cycloalkyl, or oxo (unless amide is formed); p = 0-4; CR2CR2 is a 5- or 6-membered carbocycle optionally substituted by 1-3 groups R; R3 = (un)substituted aryl or thienyl; R4 = H, alkyl, acyl, cycloalkyl, or alkoxyalkyl], or their pharmaceutically-acceptable salts or stereoisomers, which are useful in the treatment of obesity, diabetes, and male and/or female sexual dysfunction. Comps. I comprise three domains, i.e., a piperidino or piperazinyl fragment, an amino acid, and a radical CLL1(CH2)n-T. Thus, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid [1-(4-chlorobenzyl)-2-[4-[2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl]piperazin-1-yl]-2-oxoethyl]amide (claimed compd.) was prepd. via acylation of the piperazine moiety.

IT **444619-63-0P 444619-65-2P**


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of piperidiny and piperazinyl amino acid derivs. as melanocortin receptor agonists)

RN 444619-63-0 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-oxo-2-[4-[1,2,3,4-tetrahydro-2-(phenylsulfonyl)-8-isoquinolinyl]-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444619-65-2 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[4-(2-benzoyl-1,2,3,4-tetrahydro-8-isoquinolinyl)-1-piperazinyl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 444620-47-7P 444620-49-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of piperidinyl and piperazinyl amino acid derivs. as melanocortin receptor agonists)

RN 444620-47-7 CAPLUS


10/791578

CN Isoquinoline, 1,2,3,4-tetrahydro-2-(phenylsulfonyl)-8-(1-piperazinyl)-
(9CI) (CA INDEX NAME)



RN 444620-49-9 CAPLUS

CN Isoquinoline, 2-benzoyl-1,2,3,4-tetrahydro-8-(1-piperazinyl)- (9CI) (CA
INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:742072 CAPLUS

DN 133:309907

TI Preparation of nitrogen-containing heterocyclic compounds and benzamide
compounds as hypolipidemics and antiarteriosclerotics

IN Ohkura, Naoto; Hiraiwa, Yukiko; Matsushima, Tetsuya; Sasaki, Kazue;
Yamamoto, Takehiro; Shiotani, Masaharu; Suzuki, Shigeki; Nakatani, Yuuko;
Kuroda, Chizuko; Nagasawa, Mieko; Katano, Kiyoaki

PA Meiji Seika Kaisha, Ltd., Japan

SO PCT Int. Appl., 284 pp.

CODEN: PIXXD2

DT Patent



LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000061556	A1	20001019	WO 2000-JP2329	20000410
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,			

DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2369103	AA	20001019	CA 2000-2369103	20000410
BR 2000009650	A	20020102	BR 2000-9650	20000410
EP 1180514	A1	20020220	EP 2000-915465	20000410
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AU 779550	B2	20050127	AU 2000-36759	20000410
US 6777414	B1	20040817	US 2001-958296	20011005
US 2004224959	A1	20041111	US 2004-868006	20040616
PRAI JP 1999-102559	A	19990409		
JP 1999-118490	A	19990426		
JP 1999-119043	A	19990427		
WO 2000-JP2329	W	20000410		
US 2001-958296	A3	20011005		
OS MARPAT 133:309907				
GI				



AB The title compds. [I; R1 and R2 represent each (un)substituted C1-6 alkyl or alkoxy, C3-8 cycloalkyl, Ph, C2-6 alkenyl or alkynyl, 5- or 6-membered ring (un)satd. heterocyclyl; R3 and R4 represent each hydrogen, (un)substituted C1-6 alkyl, halo, OH, cyano, C2-5 alkoxy, or CO2H; or R2 and R3 may be bonded to each other to form (CH2)m, N:CH, CH:N, or (C1-6 alkyl)-C:N; wherein m is 1 or 2; A, D, E and G represent each C, or one of A, D, E and G represents N and the remainders represent C; Q represents N or C; Y represents a group represented by general formula Q1 (wherein X represents hydrogen, CONR5R6, etc.; R8 represents nil or a bond, O, etc.; and R9 and R10 represent each hydrogen, alkyl, etc.); and Z represents (CH2)n, O(CH2)i, or CONH(CH2)i; wherein n is 0-6; i is 1-6] are prepd. These compds. have an effect of inhibiting the biosynthesis of triglycerides in the liver and an effect of inhibiting the secretion of apolipoprotein B-contg. lipoproteins from the liver (the latter effect being particularly excellent), without showing the side effect of fat accumulation in the liver, and are useful in treating and preventing hyperlipemia, arteriosclerotic diseases, and pancreatitis.

Thus, to a soln. of 2-benzyl-7-[4-[4-[9-(2,2,2-trifluoroethylcarbamoyl)-9H-fluorene-9-yl]butyl]piperazin-1-yl]-3,4-dihydro-2H-isoquinolin-1-one in PhMe were added NaOH, K₂CO₃, tetrabutylammonium hydrogen sulfate, and allyl bromide and the resulting mixt. was stirred at 60.degree. overnight to give title compd. (II). II in vitro inhibited the secretion of apolipoprotein B by 89% and the biosynthesis of triglycerides by 89% in HepG2 cells. Tablet and capsule formulations were also described.

IT 301666-52-4P 301666-53-5P 301667-25-4P



301667-28-7P 301667-33-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of nitrogen-contg. heterocyclic compds. and benzamide compds. as hypolipidemics and antiarteriosclerotics and inhibitors of apolipoprotein B-contg. lipoproteins and biosynthesis of triglycerides)



RN 301666-52-4 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[1,2,3,4-tetrahydro-1-oxo-2-(phenylmethyl)-7-isoquinolinyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)





RN 301666-53-5 CAPLUS

CN 9H-Xanthene-9-carboxamide, 9-[4-[4-[1,2,3,4-tetrahydro-1-oxo-2-(phenylmethyl)-7-isoquinolinyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 301667-25-4 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[1,2,3,4-tetrahydro-1-oxo-2-(2-pyridinylmethyl)-7-isoquinolinyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)





RN 301667-28-7 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[3-[4-[1,2,3,4-tetrahydro-1-oxo-2-(2-pyridinylmethyl)-7-isoquinolinyl]-1-piperazinyl]propyl]-N-(2,2,2-

10/791578


trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 301667-33-4 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[8-chloro-1,2,3,4-tetrahydro-2-[(3-methoxyphenyl)methyl]-1-oxo-7-isoquinolinyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A






IT 217492-19-8P 301667-26-5P 301667-27-6P
301667-35-6P 301667-36-7P 301667-53-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of nitrogen-contg. heterocyclic compds. and benzamide compds. as hypolipidemics and antiarteriosclerotics and inhibitors of apolipoprotein B-contg. lipoproteins and biosynthesis of triglycerides)


RN 217492-19-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1,2,3,4-tetrahydro-1-oxo-2-(phenylmethyl)-7-isoquinolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 301667-26-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1,2,3,4-tetrahydro-1-oxo-2-(2-pyridinylmethyl)-7-isoquinolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 301667-27-6 CAPLUS


CN 1(2H)-Isoquinolinone, 3,4-dihydro-7-(1-piperazinyl)-2-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



10/791578


RN 301667-35-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[8-chloro-1,2,3,4-tetrahydro-2-[(3-methoxyphenyl)methyl]-1-oxo-7-isoquinolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 301667-36-7 CAPLUS

CN 1(2H)-Isoquinolinone, 8-chloro-3,4-dihydro-2-[(3-methoxyphenyl)methyl]-7-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 301667-53-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1,2,3,4-tetrahydro-1-oxo-2-(phenylmethyl)-6-isoquinolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:793126 CAPLUS

DN 130:52434

TI Prepn. of nitrogenous heterocyclic compounds as hyperlipemia remedies

IN Ohkura, Naoto; Tsuruoka, Takashi; Usui, Takayuki; Hiraiwa, Yukiko;
Matsushima, Tetsuya; Shiotani, Masaharu; Niizato, Tetsutaro; Nakatani,
Yuuko; Suzuki, Shigeki; Kuroda, Chidsuko; Katano, Kiyooki

PA Meiji Seika Kaisha, Ltd., Japan; et al.

SO PCT Int. Appl., 194 pp.



CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9854135	A1	19981203	WO 1998-JP2411	19980601
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2291630	AA	19981203	CA 1998-2291630	19980601
	AU 9875482	A1	19981230	AU 1998-75482	19980601
	EP 999208	A1	20000510	EP 1998-923066	19980601
	R: DE, ES, FR, GB, IT				
	US 6417362	B1	20020709	US 1999-424708	19991130
	US 2002156276	A1	20021024	US 2002-127491	20020423
	US 6583144	B2	20030624		
PRAI	JP 1997-141410	A	19970530		
	WO 1998-JP2411	W	19980601		
	US 1999-424708	A3	19991130		
OS	MARPAT 130:52434				
GI					



AB The title compds. [I; A = CR₁R₂(CH₂)_i; (wherein R₁ and R₂ each represents hydrogen or alkyl, i = 0-1), CH:CH, OCH₂, or S(O)_jCH₂ (wherein j = 0-2); B = hydrogen or halogen; X = CR₃R₄R₅, NR₆R₇, (CH₂CH:C(CH₃)CH₂)_pCH₂CH:C(CH₃)₂, alkyl, cycloalkyl, Ph, cinnamyl, or heteroaryl; Y = (CH₂)_q, CH:CH, NR₈, oxygen, or a bond; Z = carbonyl or a bond; K = alkylene or a bond; L = CH:CH or a bond; and M = hydrogen, alkyl, cycloalkyl, Ph, heterocycle, biphenyl, or diphenylmethyl; p = 0-2; q = 1-6; R₃-R₅ = hydrogen, phenyl;

R6-R7 = hydrogen, Ph, benzyl; R8 = hydrogen, C1-6 alkyl] are prepd. I inhibit the biosynthesis of triglycerides in the liver and also inhibit the secretion of lipoproteins contg. apolipoprotein B from the liver. I are hence useful for the prevention/treatment of hyperlipemia (esp. hyper-VLDL-emia) and diseases caused thereby, such as arteriosclerotic diseases, e.g., myocardial infarct, and pancreatitis. Thus, title compd. (II) was prepd. by multi-step reactions and showed 56% and 90% inhibitory activity for apolipoprotein B and triglycerides. A formulation contg. I was also presented.


IT 217492-19-8P 217492-20-1P 217492-23-4P
 217492-24-5P 217492-25-6P 217492-26-7P
 217492-28-9P 217492-29-0P 217492-31-4P
 217492-32-5P 217492-38-1P 217492-40-5P
 217492-65-4P 217492-67-6P 217492-69-8P
 217492-70-1P 217492-71-2P 217492-72-3P
 217492-73-4P 217492-74-5P 217492-75-6P
 217492-76-7P 217492-77-8P 217492-78-9P
 217492-79-0P 217492-80-3P 217492-81-4P
 217492-82-5P 217492-83-6P 217492-84-7P
 217492-85-8P 217492-86-9P 217492-87-0P
 217492-88-1P 217492-90-5P 217492-91-6P
 217492-92-7P 217492-93-8P 217492-94-9P
 217492-95-0P 217492-96-1P 217492-98-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of nitrogenous heterocyclic compds. as hyperlipemia remedies)


RN 217492-19-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1,2,3,4-tetrahydro-1-oxo-2-(phenylmethyl)-7-isoquinolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 217492-20-1 CAPLUS

CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 217492-23-4 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-(cyclohexylmethyl)-1,2,3,4-tetrahydro-1-oxo-7-isoquinolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 217492-24-5 CAPLUS

CN 1(2H)-Isoquinolinone, 2-(cyclohexylmethyl)-7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 217492-25-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-(cyclopropylmethyl)-1,2,3,4-tetrahydro-1-oxo-7-isoquinolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 217492-26-7 CAPLUS

CN 1(2H)-Isoquinolinone, 2-(cyclopropylmethyl)-7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 217492-28-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[(4-chlorophenyl)methyl]-1,2,3,4-tetrahydro-1-oxo-7-isoquinolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 217492-29-0 CAPLUS

CN 1(2H)-Isoquinolinone, 2-[(4-chlorophenyl)methyl]-7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 217492-31-4 CAPLUS

CN 1(2H)-Isoquinolinone, 2-[(2-chlorophenyl)methyl]-7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 217492-32-5 CAPLUS


CN 1(2H)-Isoquinolinone, 2-[(3-chlorophenyl)methyl]-7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 217492-38-1 CAPLUS


CN 1(2H)-Isoquinolinone, 7-[4-(4,4-diphenylbutyl)-1-piperazinyl]-3,4-dihydro-2-(phenylmethyl)- (9CI) (CA INDEX NAME)

10/791578




RN 217492-40-5 CAPLUS

CN 1(2H)-Isoquinolinone, 7-[4-[(4-chlorophenyl)methyl]-1-piperazinyl]-3,4-dihydro-2-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 217492-65-4 CAPLUS

CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)




RN 217492-67-6 CAPLUS

CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 217492-69-8 CAPLUS

CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 217492-70-1 CAPLUS

CN 1(2H)-Isoquinolinone, 2-(3,3-diphenylpropyl)-7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 217492-71-2 CAPLUS

CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-[(2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 217492-72-3 CAPLUS

CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-[(3-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 217492-73-4 CAPLUS

CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 217492-74-5 CAPLUS

CN 1(2H)-Isoquinolinone, 2-[(3,4-dimethylphenyl)methyl]-7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 217492-75-6 CAPLUS

CN 1(2H)-Isoquinolinone, 2-[(2,5-dimethylphenyl)methyl]-7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 217492-76-7 CAPLUS

CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-[(2,4,6-trimethylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 217492-77-8 CAPLUS

CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-(1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 217492-78-9 CAPLUS

CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 217492-79-0 CAPLUS

CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 217492-80-3 CAPLUS

CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-2-[(3-bromophenyl)methyl]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 217492-81-4 CAPLUS

CN 1(2H)-Isoquinolinone, 2-[(3-bromophenyl)methyl]-7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 217492-82-5 CAPLUS

CN 1(2H)-Isoquinolinone, 2-[(3,4-dichlorophenyl)methyl]-7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 217492-83-6 CAPLUS

CN 1(2H)-Isoquinolinone, 2-[(2,4-dichlorophenyl)methyl]-7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 217492-84-7 CAPLUS

CN Benzoic acid, 4-[[7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-1-oxo-2(1H)-isoquinolinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 217492-85-8 CAPLUS

CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 217492-86-9 CAPLUS

CN 1(2H)-Isoquinolinone, 2-[(3,5-dimethoxyphenyl)methyl]-7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 217492-87-0 CAPLUS

CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-[(3-hydroxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 217492-88-1 CAPLUS

CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-(2-hydroxy-2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 217492-90-5 CAPLUS

CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-(2-hydroxy-2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 217492-91-6 CAPLUS

CN 1(2H)-Isoquinolinone, 2-([1,1'-biphenyl]-2-ylmethyl)-7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 217492-92-7 CAPLUS

CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-[(tetrahydro-2H-pyran-2-yl)methyl]- (9CI) (CA INDEX NAME)




RN 217492-93-8 CAPLUS

CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-(4-thiazolylmethyl)- (9CI) (CA INDEX NAME)




RN 217492-94-9 CAPLUS

CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-[(4-methyl-5-thiazolyl)methyl]- (9CI) (CA INDEX NAME)




RN 217492-95-0 CAPLUS

CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 217492-96-1 CAPLUS

CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-2-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 217492-98-3 CAPLUS

CN 1(2H)-Isoquinolinone, 7-[4-(3,3-diphenylpropyl)-1-piperazinyl]-3,4-dihydro-4,4-dimethyl-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log h

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

16.25

17.34

10/791578

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-2.25	-2.25

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 19:42:00 ON 19 FEB 2006